MedPath

Adrenas Therapeutics, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])

Recruiting
Conditions
Congenital Adrenal Hyperplasia
First Posted Date
2021-11-01
Last Posted Date
2024-08-23
Lead Sponsor
Adrenas Therapeutics Inc
Target Recruit Count
300
Registration Number
NCT05101902
Locations
🇺🇸

Science37, Los Angeles, California, United States

A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)

Phase 1
Recruiting
Conditions
Congenital Adrenal Hyperplasia
Interventions
Biological: AAV BBP-631
First Posted Date
2021-03-05
Last Posted Date
2024-08-06
Lead Sponsor
Adrenas Therapeutics Inc
Target Recruit Count
25
Registration Number
NCT04783181
Locations
🇺🇸

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

and more 2 locations

News

No news found
© Copyright 2025. All Rights Reserved by MedPath